News > AstraZeneca’s Durvalumab receives CDSCO approval in India for treatment of patients with locally advanced or metastatic Biliary Tract Cancer

AstraZeneca’s Durvalumab receives CDSCO approval in India for treatment of patients with locally advanced or metastatic Biliary Tract Cancer

AstraZeneca India, a leading science-led biopharmaceutical company announced additional indication approval from Central Drugs Standard Control Organization (CDSCO) for Durvalumab to treat biliary tract cancer (BTC) in India. BTC is a group of rare and aggressive gastrointestinal (GI) cancers that form in the cells of the bile ducts (cholangiocarcinoma), gallbladder or ampulla of Vater (where the bile duct and pancreatic duct connect to the small intestine).